Nerandomilast bulk supplier for pharma manufacturers

Nerandomilast 10 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 10 mg

Reference Brands: Jascayd (USA/EU)

Nerandomilast is a selective phosphodiesterase-4B (PDE4B) inhibitor approved for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It slows the decline in lung function by reducing inflammatory and fibrotic signalling in the lung, and is taken orally once daily. It is not indicated for COPD.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Nerandomilast? List it or send an offer →

Product Description:

Nerandomilast is an oral preferential inhibitor of phosphodiesterase 4B, developed for pulmonary fibrosis. PDE4B is the isoform most associated with inflammatory and fibrotic signalling, and targeting it preferentially rather than inhibiting PDE4 broadly was intended to retain antifibrotic effect while reducing the gastrointestinal effects that limit non-selective PDE4 inhibitors.

The US FDA approved it in September 2025 for idiopathic pulmonary fibrosis, and subsequently for progressive pulmonary fibrosis on the basis of the FIBRONEER-ILD trial. Japan has approved both indications. It is the first genuinely new mechanism approved in IPF in over a decade, and it slows the decline in forced vital capacity rather than reversing established fibrosis.

A correction worth stating plainly: nerandomilast is not a COPD treatment and has not been approved for COPD. It is a pulmonary fibrosis product, and the distinction matters because the prescriber, the patient population and the procurement route are entirely different.

Sourcing notes. This is a newly approved, on-patent innovator product with a single manufacturer. No generic exists or lawfully can for years, and any offer of generic nerandomilast should be refused. Approvals outside the US and Japan were still progressing through 2026, so availability is strictly market-dependent. For patients in markets without approval, named-patient import is the mechanism, requiring physician documentation and regulatory authorisation in the destination country.

How Nerandomilast is supplied today, and licensing ahead of patent expiry

Nerandomilast is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Nerandomilast, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Nerandomilast supply →

Back to Listing

Frequently Asked Questions

Nerandomilast is used for the treatment of idiopathic pulmonary fibrosis (IPF). It helps slow the decline in lung function and manages disease progression.

It is made from the active molecule nerandomilast (also known as BI-1015550), a preferential phosphodiesterase-4B (PDE4B) inhibitor.

The trade name is Jascayd.

It is developed and manufactured by Boehringer Ingelheim.

The generic name is Nerandomilast.

The brand name is Jascayd.

It is manufactured by Boehringer Ingelheim in its global production facilities, with distribution in approved international markets.

Jascayd (Nerandomilast) is developed and sold by Boehringer Ingelheim. PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.